Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmacyclics (PCYC) -- Ignore unavailable to you. Want to Upgrade?

To: tnsaf who wrote (372)	9/30/1998 12:45:00 PM
From: mauser96	Respond to of 717

I like the implications of the phase III Gd-Tex trials. It shouldn't be too hard to get trial participants since the prognosis is so bleak, and it has a clear end point. Also, at the 2/3 point if it appears to be working the controls will be switched to the drug. This is one trial that won't drag on for 5 or 6 years, and even the FDA can't argue whether people are alive or dead. Even if a drug is approved ,it is often a very slow process to get cost sensitive managed care providers to use it. If a significant increased survival time is shown HMO's will be forced to use the drug. However, it's still a gamble and even if the trials turn out well profits are years away. I am dubious about TA in stocks like this, but there is some support near today's price, and we are off 50% from the highs. BTW, the news concerning the trial isn't showing up on my Charles Schwab "News Headlines" report.

To: tnsaf who wrote (372)	10/24/1998 2:12:00 AM
From: tnsaf	Read Replies (3) \| Respond to of 717

Some upcoming presentations (from PCYC's web site): American Society of Therapeutic Radiation Oncology (ASTRO) October 25-29, 1998 Phoenix, AZ October 27, 1998 2:00 p.m.-3:30 p.m. Poster Session -- Viewing Only Abstract #2071: "Pharmacokinetics of the Radiation Sensitizer Gadolinium Texaphyrin in a Phase Ib/II Trial for Patients with Brain Metastases Receiving Whole Brain Radiation" Abstract #2072: "Selective Uptake and Retention of the Radiation Sensitizer Gadolinium Texaphyrin (Gd-Tex) in Tumors Demonstrated by MRI in Phase I and II Clinical Trials" October 28, 1998 2:30 p.m. Oral Presentation #147 "Phase Ib/II Trial of the Radiation Sensitizer Gadolinium Texaphyrin (Gd-Tex) for Patients with Brain Metastases: Final Results" NOVEMBER American Heart Association (AHA) November 8-11, 1998 Dallas, TX November 9, 1998 9:15 a.m.-9:30 a.m. Oral Presentation #500973 "Photoangioplasty with ANTRINTM: A Photosensitizer that Selectively Accumulates in Atheromatous Plaque and is Detectable by Fluorescence Imaging" November 9, 1998 9:30 a.m.-9:45 a.m. Oral Presentation #501065 "Photoangioplasty of Human Atherosclerosis with ANTRINTM" Society of Neuro-Oncology (SNO) November 15, 1998 San Francisco, CA November 15, 1998 10:15 a.m.-10:30 a.m. Oral Presentation "Gadolinium Texaphyrin (Gd-Tex), A Tumor Selective Radiation Sensitizer for Primary and Metastatic Brain Tumors"